In the preceding funding period we have identified recurrent mutations and copy number increases of KIT in 30-40% of melanomas arising on chronically sun-damaged skin (CSD), acral sites. Emerging clinical evidence indicates that these genetic alterations are a strong indicator for clinical responses to already approved KIT inhibitors. By contrast, KIT alterations are absent in melanoma arising on the non-CSD skin, which frequently harbor BRAF mutations, identifying them as biologically distinct. Differences in mutation spectra, chromosomal aberrations, and clinical and histopathological presentation implicate the KIT pathway as an important contributor in acral, mucosal, and CSD melanoma types. Despite these advances, the oncogenic alterations in the majority of these melanomas are currently not known as they infrequently harbor BRAF mutations. Preliminary studies implicate additional genes downstream of KIT as candidate genes, including the scaffolding protein GAB2, the protein phosphatase SHP2, amplification of the two p70S6 kinase genes as additional targets for somatic activation. We hypothesize that together these findings indicate a wider role for KIT pathway activation in these melanoma types, which would have therapeutic and diagnostic implications. We will validate the contribution of genetic alterations in the KIT pathway to the malignant phenotype and response to therapy and aim to discover additional alterations. Our studies will involve comprehensive genomic characterization of archival tissues to identify genetic alterations and determine in which combination they occur (aim 1), functional analyses in vitro models representing the most common of the findings in human tumors to characterize their effect on sensitivity and resistance to targeted agents (aim 2), and tumor samples from patients with KIT alterations who were treated with KIT inhibitors, to determine factors of primary and secondary resistance to treatment in a clinical setting (aim 3).

Public Health Relevance

Characterization of the somatic genetic alterations in melanoma and their role in oncogenesis, therapeutic targets or biomarkers for resistance to specific therapies is of direct clinical relevance for the treatment and management of patients with metastatic melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA025874-33
Application #
8627551
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
33
Fiscal Year
2014
Total Cost
$572,333
Indirect Cost
$255,987
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Heppt, Markus V; Wang, Joshua X; Hristova, Denitsa M et al. (2018) MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. J Invest Dermatol 138:141-149
Ca├▒adas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Krepler, Clemens; Sproesser, Katrin; Brafford, Patricia et al. (2017) A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Rep 21:1953-1967
Somasundaram, Rajasekharan; Zhang, Gao; Fukunaga-Kalabis, Mizuho et al. (2017) Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 8:607

Showing the most recent 10 out of 382 publications